Biotechnology
Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST
New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention
Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?
Read
Commented by Stefan Bode on September 10th, 2026 | 08:30 CEST
A Plunge, Corporate Restructuring, and a Bet on Technology – Novartis, HPQ Silicon, Volkswagen
In the stock market, it is often not the big promises but the critical transition phases that determine investment opportunities—true to the saying: "The profit lies in the purchase." That is exactly where the following three stocks stand. A corporation with costly pipeline risk, a tech stock on the path from testing to potential commercialization, and an industrial giant in the midst of a tough restructuring. Investors looking to understand where hope, risk, and revaluation are currently most strongly intertwined will find interesting case studies here.
Read
Commented by Nico Popp on September 9th, 2026 | 07:30 CEST
Biotech Boom Thanks to Synergies: AstraZeneca Bets on Platforms, Almirall Forges Alliances, and Vidac Pharma Has the Multi-Tool
Everyone in Germany knows the situation: doctors' offices are crowded, and the healthcare system is stretched to its limits. But even when waiting rooms are full, there are still rays of hope. In Europe, research is being conducted successfully in many areas. As standard drugs gradually lose their patent protection, a new era is dawning. While cutting-edge research in Germany is still considered brilliant, it has all too often failed to translate findings into products. But that is changing. A new generation of European pharmaceutical players is closing the gap with the competition and showing that groundbreaking therapeutic advances no longer have to come exclusively from overseas. We take a look at some exciting companies.
Read
Commented by Fabian Lorenz on September 9th, 2026 | 07:00 CEST
Evotec Under Pressure! Analysts See Upside Potential - News From MustGrow and Bayer
Created and Published on Behalf of MustGrow Biologics Corp.
Alarm bells are ringing at Evotec. The share price is at risk of slipping below the EUR 3 mark. Even at this seemingly low price level, analysts are notably reluctant to issue "Buy" recommendations. Evotec has, however, announced a research collaboration to develop new T-cell-activating therapeutic approaches for solid tumors. MustGrow's story is now gaining noticeable momentum. The Canadian AgTech company reached profitability in the first half of the year and expects revenue to increase in the second half. In addition, the first milestone payment from Bayer under their licensing agreement has been received. Further payments running into the millions could follow in the coming years and exceed MustGrow's current market capitalization. Analysts see potential for significant upside. Bayer itself has announced an intensive phase of new product launches for its Crop Science division. Analysts recommend buying the stock.
Read
Commented by André Will-Laudien on September 8th, 2026 | 09:40 CEST
Biotech: Time to Bet on the Rebound! Evotec and BioNxt in the Takeover Spotlight, Bayer and BioNTech Flush with Cash
After a long dry spell, the biotech sector is on the cusp of a spectacular turnaround, offering bold investors the potential for significant returns. Many innovative biotech stocks are trading well below their all-time highs, yet almost unnoticed, the next major rally is already taking shape behind the scenes. The huge cash reserves of industry giants Bayer and BioNTech are currently fueling takeover speculation across the sector. This colossal capital, running into the billions, is desperately seeking new growth drivers, suddenly putting smaller players on the radar of potential acquirers. At the very top of the hunters' watchlist are the hard-hit Evotec and the disruptive newcomer BioNxt. Both companies boast top-class technology platforms, which, at current levels, almost seem like an exclusive clearance sale. Investors who keep their eyes open and position themselves strategically for the major rebound could get ahead of the looming wave of consolidation. The conditions for an explosive catch-up rally have rarely been this favorable.
Read
Commented by Fabian Lorenz on September 1st, 2026 | 07:45 CEST
Potential Moderna-Style Share Surge? Takeover Candidates Evotec, Valneva and Vidac Pharma in Focus — Analysts Bullish
Moderna has shaken up the biotech market with its breakthrough in the fight against skin cancer. Partner Merck has received somewhat less attention in the coverage, despite preparing for the eventual patent expiration of one of its blockbuster drugs. Other pharmaceutical companies will also need to replenish their pipelines in the coming years. As a result, the takeover merry-go-round is likely to pick up speed again, potentially electrifying investors. One hot candidate is Vidac Pharma. Recruitment for its Phase 2B trial into high-risk actinic keratosis, a precancerous skin condition, has been completed. The results could provide a catalyst for the stock. Valneva's share price has recently risen sharply. Could its partner Pfizer eventually make a move? Analysts are recommending the stock. And what about perennial takeover candidate Evotec? Shareholders and potential buyers are currently giving the share a wide berth. Yet there is a "Buy" recommendation on the table.
Read
Commented by Matthias Schomber on August 31st, 2026 | 06:55 CEST
Market Opportunities and Contrasts: Novo Nordisk with Weight-Loss Pill, ASIC Concerns at DroneShield, Power Metallic Mines with Breakout Potential
Danish pharmaceutical giant Novo Nordisk has suffered a significant setback in the fierce race for the lucrative weight-loss drug market, but its new weight-loss pill could now prove to be a game changer. At the same time, Australian drone specialist DroneShield is facing regulatory headwinds that are severely testing investor confidence, yet the numbers remain strong. Away from these companies, Canada's resource sector has another standout in Power Metallic Mines, which is demonstrating impressively how a solid polymetallic discovery and excellent drilling results can inject strength and momentum into a stock chart performance. Read on to find out why these three stocks deserve a place on every watchlist right now!
Read
Commented by Fabian Lorenz on August 31st, 2026 | 06:45 CEST
Shock at BioNTech! Insider Buying at Nordex! Comeback Story for dynaCERT!
Could dynaCERT become the comeback story of the year? Analysts at GBC Research certainly believe the cleantech stock could rise to EUR 0.48. The shares are currently trading at EUR 0.06. The company's German management team is working hard to engineer a comeback. In particular, it has recently celebrated successes in commercializing its technology in Vietnam and Mexico. Further positive news should follow in the coming months. BioNTech, on the other hand, shocked its shareholders with Friday's announcement. The Phase 2 trial of its cancer immunotherapy candidate for colorectal cancer has been halted. Does this mean the mRNA race against Moderna is lost? The Nordex share has also recently lost momentum. The stock has been moving sideways since February. But now an insider purchase is attracting attention. Not all analysts, however, share the optimism.
Read
Commented by Lars Winter on August 26th, 2026 | 07:20 CEST
Money, Money, Money: RE Royalties, Aumann and Pfizer Put Dividend Investors in the Money
Dividends are far more than just a consolation prize during weak market phases. Profit distributions typically account for a large portion of a stock's total return. In addition, dividends generally fluctuate much less than earnings and share prices. A high yield alone, however, is not a seal of quality. It can also result from a sharp drop in the share price, an overextended payout ratio, or an impending cut. Many dividend enthusiasts therefore also seek reliability. The three selected dividend stocks cover different strategies: RE Royalties entices with a double-digit yield and the greatest upside potential, but also carries the highest risk. Aumann, on the other hand, is a short-term speculative play offering a generous special dividend, largely financed by its well-stocked cash reserves. Pfizer, in contrast, offers the lowest yield of the trio but boasts the longest and most reliable dividend history. We take a closer look at these stocks.
Read
Commented by André Will-Laudien on August 25th, 2026 | 09:15 CEST
Biotech M&A Boom: Novo Nordisk & Eli Lilly Battle for Market Share — BioNxt and Evotec on the Radar
As the recent spectacular USD 43 billion acquisition of cancer specialist Seagen by Pfizer and the mega-deals surrounding the GLP-1 infrastructure impressively demonstrate, the pharmaceutical industry is in the midst of a historic wave of consolidation. Driven by the massive, billion-dollar profits from the weight-loss injection market, an unprecedented wave of acquisitions has now begun. Market leaders such as Novo Nordisk and Eli Lilly are using their well-stocked war chests to pursue strategic mega-acquisitions to secure their dominant positions and systematically eliminate production bottlenecks. At the same time, highly innovative platform companies like BioNxt are coming into focus with their novel delivery systems. Strategically valuable targets currently trading at attractive valuations, such as Evotec, have long been in the crosshairs of investors and competitors. Those who do not want to be left behind in the battle for market share, new delivery technologies, and the next generation of blockbuster drugs must make acquisitions now, because the M&A carousel is spinning faster than it has in a long time. We dig a little deeper!
Read